CHA Healthcare

About CHA Healthcare

CHA Healthcare is the global expansion and management arm of the South Korean CHA Medical Group, operating a network of general hospitals and specialized fertility clinics. The company was established in 2013 as a subsidiary of CHA Biotech to manage and expand the group's international presence. The broader CHA Medical Group was founded in 1960 by Dr. Kwang-yul Cha, evolving from a single OB/GYN clinic into a global healthcare entity renowned for its work in fertility and reproductive medicine. The group operates 81 medical centers and clinics across seven countries. CHA Healthcare's business model is centered on providing a comprehensive spectrum of medical services, from acute hospital care to specialized fertility treatments. Revenue is generated through patient services at its network of facilities. A key part of its strategy involves both organic growth and inorganic expansion through mergers and acquisitions. A significant move into the Australian market occurred in 2018 with the acquisition of a majority stake in City Fertility, which at the time operated seven fertility centers. This was a joint venture with Singapore Medical Group. CHA Healthcare has since expanded its Australian footprint, acquiring Fertility Specialists of Western Australia (FSWA) in 2022, bringing its total to 18 fertility centers across the country, including in major cities like Brisbane, Melbourne, and Sydney. Through its subsidiary City Fertility, CHA Healthcare offers a wide array of services including In Vitro Fertilisation (IVF), Intracytoplasmic Sperm Injection (ICSI), fertility testing, egg and sperm freezing, and access to donor banks. This Australian network performs thousands of IVF treatments annually, with plans to conduct over 10,000 per year by 2026. Beyond Australia, the company manages facilities like the CHA-Hollywood Presbyterian Medical Center in Los Angeles and has a presence in Japan and Singapore, with further expansion planned for Southeast Asia. The company leverages the advanced medical technology and research capabilities of the wider CHA Group, dispatching Korean medical professionals to its international locations to implement its treatment techniques.